CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-04-16): Methotrexate and isoniazid safe in rheumatoid arthritis patients with TB

Clinical

Methotrexate and isoniazid safe in rheumatoid arthritis patients with TB

Last Updated: 2008-04-16 17:14:27 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients on methotrexate for rheumatoid arthritis (RA), concomitant treatment with isoniazid for latent or active TB appears to be well tolerated, researchers report in the April issue of the Annals of the Rheumatic Diseases.

This is of particular importance, senior investigator Dr. Pamela B. Rosenthal told Reuters Health, in light of the possible reactivation of TB with tumor necrosis factor blockers. "The potentially devastating consequences of an active TB infection are of heightened concern to physicians, who prescribe anti-tumor necrosis factor medications, and patients alike."

Dr. Rosenthal of New York University School of Medicine, New York and colleagues point out that both methotrexate and isoniazid are potentially hepatotoxic and data on combined treatment are lacking.

The researchers sought to examine the safety of isoniazid therapy in RA patients on methotrexate, before initiation of the tumor necrosis factor antagonist therapy.

The team retrospectively studied data on 44 patients who were concomitantly treated with methotrexate for RA and isoniazid for active or latent TB. All had normal liver function test results at baseline.

Transient increases in liver function tests were seen in 11% of the patients, but these did not go beyond twice the upper limit of normal values and all resolved spontaneously.

Among the patients who went on to treatment with etanercept or adalimumab, no reactivation of TB was observed.

The researchers conclude that the additive risk of hepatotoxicity with isoniazid added to methotrexate is low, but nonetheless, they stress that "it is prudent to follow liver function tests closely" in patients taking this combination.

Ann Rheum Dis 2008;67:462-465.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.